search
Back to results

Patient Decision Aid for Antidepressant Use in Pregnancy

Primary Purpose

Pregnancy, Depression

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Electronic Patient Decision Aid
Standard Resource Sheet
Sponsored by
Women's College Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Pregnancy focused on measuring Pregnancy, Depression, Antidepressant Use, Decision Aid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria:

  1. Are females aged >18 years old, and
  2. Are either planning a pregnancy OR are <30 weeks gestation at enrollment, and
  3. Have been offered to start or continue SSRI or SNRI anti-depressant medication as a treatment option for depression by their clinical provider at one of the study sites, and
  4. Have moderate-to-high decisional conflict (score of >25 on the Decisional Conflict Scale)

Exclusion criteria:

  1. Have had alcohol or substance abuse or dependence in the previous 12 months, or
  2. Have active suicidal ideation or psychosis, or
  3. Are incapable of consenting to participation, or
  4. Have any major obstetrical complications or fetal cardiac anomaly in the current or in a past pregnancy (as this changes the risk/benefit ratio discussion in regards to antidepressant use), or
  5. Are unable to read or unable to speak or understand English and do not have someone that can read the PDA to them, or
  6. Have a visual impairment that would prevent them from being able to view the website.

Sites / Locations

  • Women's College Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Standard Resource Sheet

Electronic Patient Decision Aid

Arm Description

Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).

The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important. At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.

Outcomes

Primary Outcome Measures

Recruitment Rate
Feasibility: Number of participants recruited into the study over Number of eligible patients

Secondary Outcome Measures

Decisional Conflict Scale
Knowledge about antidepressant treatment in pregnancy
Edinburgh Postnatal Depression Scale
Spielburg State-Trait Anxiety Inventory
Edinburgh Postnatal Depression Scale
Edinburgh Postnatal Depression Scale
Spielburg State-Trait Anxiety Inventory
Spielburg State-Trait Anxiety Inventory
Decisional Conflict Scale
Knowledge about antidepressant treatment in pregnancy
PDA Acceptability Questionnaire
Provider Perspective Survey
Treatment Decision(s)
Treatment Decision(s)
Treatment Decision(s)
Time between recruitment to first log-in to the study website
Self-reported satisfaction with the PDA by the participants
Provider's perspective on the utility of the PDA in clinical practice
Study Website Usage
Composite measure comprised of: (1) number of participants who complete the PDA, (2) length of time required to complete the PDA, (3) number of log ins, (4) number of times the PDA is completed per participant, (5) total number of webpages viewed).
Number of participants who follow-up with their physician during the intended timeline
The rate of follow-up data collection
The rate of follow-up data collection

Full Information

First Posted
December 2, 2014
Last Updated
May 11, 2017
Sponsor
Women's College Hospital
Collaborators
Ontario Ministry of Health and Long Term Care, Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT02308592
Brief Title
Patient Decision Aid for Antidepressant Use in Pregnancy
Official Title
Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
April 2017 (Actual)
Study Completion Date
April 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Women's College Hospital
Collaborators
Ontario Ministry of Health and Long Term Care, Canadian Institutes of Health Research (CIHR)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this pilot study is to examine the feasibility of conducting a multi-site randomized controlled trial whose aim will be to evaluate the effectiveness of a Patient Decision Aid (PDA) for antidepressant use in pregnancy.
Detailed Description
Depression in pregnancy is common, affecting up to 10% of women and represents serious risk to mother and infant. Unfortunately, antidepressant medication, a first-line treatment for depression in pregnancy, also comes with risks, making this a complex decision. Clinical care appears to be insufficient for ensuring that women make decisions that are consistent with their own values and with which they feel satisfied. Patient decision support tools can address such barriers. We have created a patient decision aid (PDA) that has the potential to improve the decision-making process for women regarding antidepressant use in pregnancy in conjunction with clinical care. The overall objective of this project is to inform the development of a larger, international RCT to assess the efficacy of our PDA for antidepressant use in pregnancy. To achieve this objective, we will assess the feasibility of our clinical trial protocol to evaluate the PDA and determine the preliminary effect size for a larger multi-site efficacy study. The primary outcome for this pilot study is the feasibility of conducting a large randomized controlled trial to evaluate the efficacy of the PDA. This includes feasibility (how well the trial protocol can be implemented), acceptability (usability and tolerability of the intervention) and adherence (the degree to which the trial protocol is followed). We hypothesize that our protocol will be feasible, that the PDA will have a high degree of acceptability, and that adherence to the protocol will be high.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Depression
Keywords
Pregnancy, Depression, Antidepressant Use, Decision Aid

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard Resource Sheet
Arm Type
Placebo Comparator
Arm Description
Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
Arm Title
Electronic Patient Decision Aid
Arm Type
Active Comparator
Arm Description
The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important. At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.
Intervention Type
Behavioral
Intervention Name(s)
Electronic Patient Decision Aid
Intervention Description
The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
Intervention Type
Behavioral
Intervention Name(s)
Standard Resource Sheet
Intervention Description
Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA). Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.
Primary Outcome Measure Information:
Title
Recruitment Rate
Description
Feasibility: Number of participants recruited into the study over Number of eligible patients
Time Frame
Up to one year from when the study starts enrolling participants
Secondary Outcome Measure Information:
Title
Decisional Conflict Scale
Time Frame
Baseline (pre-randomization)
Title
Knowledge about antidepressant treatment in pregnancy
Time Frame
Baseline (pre-randomization)
Title
Edinburgh Postnatal Depression Scale
Time Frame
Baseline (pre-randomization)
Title
Spielburg State-Trait Anxiety Inventory
Time Frame
Baseline (pre-randomization)
Title
Edinburgh Postnatal Depression Scale
Time Frame
4 Weeks post-randomization
Title
Edinburgh Postnatal Depression Scale
Time Frame
12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
Title
Spielburg State-Trait Anxiety Inventory
Time Frame
4 Weeks post-randomization
Title
Spielburg State-Trait Anxiety Inventory
Time Frame
12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
Title
Decisional Conflict Scale
Time Frame
4 Weeks post-randomization
Title
Knowledge about antidepressant treatment in pregnancy
Time Frame
4 Weeks post-randomization
Title
PDA Acceptability Questionnaire
Time Frame
4 Weeks post-randomization
Title
Provider Perspective Survey
Time Frame
After all other participant data has been collected
Title
Treatment Decision(s)
Time Frame
Baseline (pre-randomization)
Title
Treatment Decision(s)
Time Frame
4 Weeks post-randomization
Title
Treatment Decision(s)
Time Frame
12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
Title
Time between recruitment to first log-in to the study website
Time Frame
4 weeks post-randomization
Title
Self-reported satisfaction with the PDA by the participants
Time Frame
4 Weeks post-randomization
Title
Provider's perspective on the utility of the PDA in clinical practice
Time Frame
After all participant data has been collected
Title
Study Website Usage
Description
Composite measure comprised of: (1) number of participants who complete the PDA, (2) length of time required to complete the PDA, (3) number of log ins, (4) number of times the PDA is completed per participant, (5) total number of webpages viewed).
Time Frame
4 Weeks post-randomization
Title
Number of participants who follow-up with their physician during the intended timeline
Time Frame
4 weeks post-randomization, only for participants who are seeing specialty psychiatric services
Title
The rate of follow-up data collection
Time Frame
4 Weeks post-randomization
Title
The rate of follow-up data collection
Time Frame
12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), OR at 4 weeks post-randomization for women who are NOT seeing specialty perinatal psychiatry services

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Are females aged >18 years old, and Are either planning a pregnancy OR are <30 weeks gestation at enrollment, and Have been offered to start or continue SSRI or SNRI anti-depressant medication as a treatment option for depression by their clinical provider at one of the study sites, and Have moderate-to-high decisional conflict (score of >25 on the Decisional Conflict Scale) Exclusion criteria: Have had alcohol or substance abuse or dependence in the previous 12 months, or Have active suicidal ideation or psychosis, or Are incapable of consenting to participation, or Have any major obstetrical complications or fetal cardiac anomaly in the current or in a past pregnancy (as this changes the risk/benefit ratio discussion in regards to antidepressant use), or Are unable to read or unable to speak or understand English and do not have someone that can read the PDA to them, or Have a visual impairment that would prevent them from being able to view the website.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone Vigod, MD, MSc
Organizational Affiliation
Women's College Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Women's College Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5S 1B2
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
30913472
Citation
Vigod SN, Hussain-Shamsy N, Stewart DE, Grigoriadis S, Metcalfe K, Oberlander TF, Schram C, Taylor VH, Dennis CL. A patient decision aid for antidepressant use in pregnancy: Pilot randomized controlled trial. J Affect Disord. 2019 May 15;251:91-99. doi: 10.1016/j.jad.2019.01.051. Epub 2019 Mar 18.
Results Reference
derived
PubMed Identifier
26923796
Citation
Vigod S, Hussain-Shamsy N, Grigoriadis S, Howard LM, Metcalfe K, Oberlander TF, Schram C, Stewart DE, Taylor VH, Dennis CL. A patient decision aid for antidepressant use in pregnancy: study protocol for a randomized controlled trial. Trials. 2016 Feb 29;17(1):110. doi: 10.1186/s13063-016-1233-4.
Results Reference
derived

Learn more about this trial

Patient Decision Aid for Antidepressant Use in Pregnancy

We'll reach out to this number within 24 hrs